Log in
Enquire now
‌

US Patent 9260502 Protease-stabilized insulin analogues

Patent 9260502 was granted and assigned to Novo Nordisk on February, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Novo Nordisk
Novo Nordisk
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9260502
Date of Patent
February 16, 2016
Patent Application Number
12922106
Date Filed
March 13, 2009
Patent Citations Received
‌
US Patent 11752216 Insulin analog complex with reduced affinity for insulin receptor and use thereof
‌
US Patent 12059452 Fusion proteins
0
Patent Primary Examiner
‌
Satyanarayana R Gudibande
Patent abstract

The present invention relates to novel insulin analogs comprising mutations at position A14 in the A chain and at positions B27, B28, B29 and B30 in the B chain and exhibiting resistance towards protease; a method for the preparation of such insulin analogs; insulin preparations containing the insulin analogs of the invention; and, a method of treating diabetes mellitus using these insulin analogs.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9260502 Protease-stabilized insulin analogues

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.